Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siang Chen

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
ESC Heart Failure|July 4, 2020
Elevated plasma phenylalanine predicts mortality in critical patients with heart failureWei-Siang Chen, Chao-Hung Wang, Chi-Wen Cheng, et al.
Cardiovascular Endocrinology & Metabolism|June 29, 2026
Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trialWei-Siang Chen, Ning-I Yang, Subodh Verma, et al.
IEEE Transactions on Biomedical Circuits and Systems|November 14, 2022
A Wireless Soil pH and Conductance Monitoring Chip Powered by Soil Microbial and Photovoltaic Energy CellsTing-Heng Lu, Chi-Wei Liu, Chuan-Yi Wu, et al.
Circulation|November 6, 2022
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical TrialKim A Connelly, C David Mazer, Pankaj Puar, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
ESC Heart Failure|July 4, 2020
Elevated plasma phenylalanine predicts mortality in critical patients with heart failureWei-Siang Chen, Chao-Hung Wang, Chi-Wen Cheng, et al.
Cardiovascular Endocrinology & Metabolism|June 29, 2026
Proteomics analysis of empagliflozin in patients without diabetes or overt heart failure from empagliflozin and cardiac remodeling in people without diabetes CardioLink-7 randomized clinical trialWei-Siang Chen, Ning-I Yang, Subodh Verma, et al.
IEEE Transactions on Biomedical Circuits and Systems|November 14, 2022
A Wireless Soil pH and Conductance Monitoring Chip Powered by Soil Microbial and Photovoltaic Energy CellsTing-Heng Lu, Chi-Wei Liu, Chuan-Yi Wu, et al.
Circulation|November 6, 2022
Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical TrialKim A Connelly, C David Mazer, Pankaj Puar, et al.
Pageof 7